BioTuesdays
Titan Pharmaceuticals Logo

FDA panel to review NDA for Probuphine

The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...

ciclofilin pharma

Ciclofilin Pharma forms liver disease SAB

Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug...

Kitov Pharma

Kitov Pharma prices U.S. IPO

Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) has priced an initial public offering of 3,158,900 American Depository Shares (ADS) and warrants to purchase up to 3,158,900 ADS for gross proceeds expected to be...

Can-Fite

Can-Fite expands development of CF102 into NASH

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment...

Viking Therapeutics Logo

Viking, Kennedy Krieger to collaborate in X-ALD

Viking Therapeutics (NASDAQ:VKTX) and the Kennedy Krieger Institute announced a sponsored research collaboration focused on evaluating Viking’s thyroid beta agonists for the treatment of X-linked adrenoleukodystrophy (X...

Viking Therapeutics Logo

Viking submits IND for Phase 2 trial of VK2809

Viking Therapeutics (NASDAQ:VKTX) has submitted an IND application to the FDA to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. Viking expects to initiate the Phase 2...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.